Clinical Trials · NCT05161429
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
- Phase
- N/A
- Recruitment status
- Unknown
- Sponsor
- Brigham and Women's Hospital
- Enrollment
- 550,000
- Start date
- Jul 2021
- Locations
- 5 sites, United States
- Primary endpoint
- 4-point major adverse cardiac events (MACE)